![]() |
市場調查報告書
商品編碼
2177782
寵物代謝健康市場預測至2034年-全球分析(按產品類型、健康狀況、寵物品種、護理環境、診斷和監測工具、專業通路和地區分類)Pet Metabolic Health Market Forecasts to 2034 - Global Analysis By Product Category, Health Condition, Pet Type, Care Setting, Diagnostic and Monitoring Tool, Professional Channel, and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球寵物代謝健康市場規模將達到 12 億美元,並在預測期內以 7.9% 的複合年成長率成長,到 2034 年將達到 22 億美元。
該市場涵蓋糖尿病以外的代謝和內分泌疾病的診斷、治療和營養解決方案,包括內分泌藥物、實驗室檢測組合和代謝補充劑。這些產品用於支持甲狀腺疾病、血脂異常症及相關代謝性疾病的檢測和持續管理。市場成長反映了診斷服務的普及性和對綜合慢性病管理需求的不斷成長。未來的市場滲透率將取決於技術的成熟度、客戶信心、定價以及服務網路的覆蓋範圍。
人們對伴侶動物慢性代謝疾病的認知不斷提高
寵物代謝健康的需求源於識別和管理伴侶動物疾病的需要,例如糖尿病、甲狀腺功能障礙以及血脂和血糖異常。獸醫診所透過血液和尿液檢查檢測來評估代謝狀況,治療方案可能包括藥物治療、治療性飲食和定期監測。當體重變化、飲水量變化、食慾變化和嗜睡等症狀持續存在時,寵物飼主往往會尋求持續的治療。因此,診斷產品、實驗室服務和疾病特異性飲食在護理過程中發揮著相互關聯的作用。慢性疾病的管理也帶來了持續監測和治療支援的需求。
診斷難題、治療費用、飼主。
代謝性疾病難以識別,因為體重波動、口渴加劇和活動量減少等徵兆可能與其他疾病和正常老齡化重疊。診斷可能需要臨床檢查和重複測量,這不僅費用高昂,而且需要獸醫服務。治療可能包括每日服藥、注射胰島素、飲食管理和定期監測,這對飼主來說可能是一個持續的負擔。此外,貓和狗對治療的反應可能有所不同,需要調整劑量和飲食。追蹤不足會使疾病管理變得困難,而某些地區獸醫檢測實驗室的匱乏也會阻礙及時診斷。
綜合診斷、治療性營養管理和預防性獸醫護理。
協調診斷檢測、治療性營養和長期獸醫監測蘊藏著巨大的機會。即時檢測使診所能夠在就診期間評估血糖值和相關代謝指標,並可根據需要使用實驗室檢測進行更詳細的評估。對於患有糖尿病、肥胖相關代謝紊亂或血脂異常症的動物,疾病特異性飲食可以作為治療的輔助。數位化提醒和連網監測工具可以幫助飼主更好地安排用藥、餵食和檢測時間。能夠連接獸醫醫院、診斷實驗室和寵物營養供應商的機構可以提供比單一產品更全面的管理方案。
監管監督和與現有獸醫醫療的競爭
當飼主選擇一般保健食品、居家監測或延遲就診而非進行系統診斷和治療時,這些替代療法可能會與專門針對代謝健康的產品形成競爭。對居家檢測結果的錯誤解讀可能導致虛假的安心感或不必要的擔憂,而未經證實的補充劑可能會分散用於臨床合理治療的資金。診斷服務提供者也面臨現有獸醫實驗室和由動物醫院獨立運作的檢測系統的競爭。檢測方案和臨床建議的變更可能會降低某些產品的效用。企業必須確保其分析的可靠性、清晰的解讀指南以及與獸醫工作流程的兼容性,才能維護行業信任。
新冠疫情擾亂了獸醫預約安排、寵物專賣店、旅遊業和寵物護理供應鏈,同時也促使人們更多地轉向線上購買和尋求建議。雖然一些飼主推遲了非必要的服務,但居家時間的增加和對動物健康意識的提高推動了對居家產品和數位化支援的需求。企業紛紛回應,推出了電子商務、遠距醫療和靈活的預約安排。隨著限制措施的逐步放寬,離線服務逐漸恢復,但人們對便利性和清晰產品資訊的需求仍然存在。疫情的影響因市場而異,取決於臨床需求、自由裁量權支出以及在條件允許的情況下對線下體驗的依賴程度。
在預測期內,內分泌和代謝治療領域預計將佔據最大的市場佔有率。
在預測期內,內分泌和代謝治療領域預計將佔據寵物代謝健康市場最大的佔有率。這一地位反映了該領域對目標伴侶動物群體的重要性,以及其主要產品類型的廣泛應用範圍。成熟的產品供應、飼主的熟悉度和專家推薦支撐了市場需求,而多樣化的照護需求則推動了重複購買和服務利用。預計參與企業市場的企業將透過有針對性的產品開發、拓展分銷網路和提供更清晰的使用指南來優先發展該領域。
預計在預測期內,「代謝合併症」細分市場將呈現最高的複合年成長率。
預計在預測期內,「代謝合併症」細分市場將呈現最高的複合年成長率,這主要得益於醫療服務提供者拓展其針對性解決方案,並透過獸醫診所、專科零售商和數位化管道提升服務可近性。推動市場需求成長的因素包括:人們對相關需求的認知不斷提高、產品配方和服務交付的改進,以及飼主越來越願意為寵物提供個人化照護。隨著便利性和可近性的提升,該細分市場有望吸引新的參與者,並促使現有醫療服務提供者拓展其產品組合。
北美預計將佔據寵物代謝健康市場最大的佔有率,這得益於其較高的寵物擁有率、相對完善的獸醫基礎設施、成熟的寵物專賣零售商以及較高的單隻寵物消費支出。美國是主要的需求中心,這得益於其獸醫診所和線上寵物護理平台的飼主,以及種類繁多的專業產品和服務。加拿大憑藉其成熟的寵物護理生態系統和成熟的伴侶動物保健服務提供商,也為市場做出了貢獻。保險的普及、消費者意識的提高以及產品創新也促進了市場滲透,儘管滲透率會因收入、地區和獸醫服務的可及性而有所不同。
在亞太地區,寵物代謝健康市場預計將實現強勁成長,這主要得益於寵物擁有率的提高、都市區城市化進程的加快、獸醫服務的普及以及主要市場有組織寵物零售業的發展。中國、日本、韓國、印度和澳洲的市場滲透管道各不相同,這反映了各國在購買力、獸醫基礎設施、產品監管以及數位商務角色方面的差異。人們對預防性護理意識的提高以及對高階伴侶動物產品需求的成長預計將推動市場發展。市場擴張將取決於在地化產品、專業教育以及對國家動物健康和消費者保護法規的遵守情況。
According to Stratistics MRC, the Global Pet Metabolic Health Market is accounted for $1.2 billion in 2026 and is expected to reach $2.2 billion by 2034 growing at a CAGR of 7.9% during the forecast period. The market covers diagnostic, therapeutic and nutritional solutions for metabolic and endocrine disorders beyond diabetes, including endocrine medicines, laboratory panels, and metabolic supplements. It is used to support detection and ongoing management of thyroid, lipid and related metabolic conditions. Growth reflects greater diagnostic access and demand for integrated chronic-disease management. Further uptake will be shaped by technology readiness, customer confidence, pricing and the breadth of service networks.
Increasing recognition of chronic metabolic conditions in companion animals
Demand in pet metabolic health is supported by the need to identify and manage disorders such as diabetes mellitus, thyroid dysfunction and lipid or glucose abnormalities in companion animals. Veterinary clinics use blood and urine testing to assess metabolic status, while treatment plans may combine medication, therapeutic nutrition and repeat monitoring. Pet owners increasingly seek ongoing management when symptoms such as weight change, altered thirst, appetite shifts or lethargy persist. Diagnostic products, laboratory services and condition-specific diets therefore serve connected parts of the care pathway. Chronic disease management creates recurring demand for monitoring and treatment support.
Diagnostic gaps, treatment costs and long-term owner compliance
Metabolic disorders can be difficult to identify because signs such as weight fluctuation, increased thirst and reduced activity overlap with other illnesses or normal ageing. Diagnosis may require laboratory testing and repeat measurements, adding cost and requiring access to veterinary services. Treatment can involve daily medication, insulin administration, controlled feeding and regular monitoring, which places a continuing burden on owners. Cats and dogs may also respond differently to treatment, requiring dose or diet adjustments. Inconsistent follow-up can compromise disease control, while limited access to veterinary laboratories restricts timely diagnosis in some locations.
Integrated testing, therapeutic nutrition and preventive veterinary care
An important opportunity lies in linking diagnostic testing with therapeutic nutrition and longitudinal veterinary monitoring. Point-of-care assays can help clinics assess glucose or related metabolic indicators during consultations, while laboratory panels support more detailed evaluation when required. Condition-specific diets can complement treatment for animals with diabetes, obesity-related metabolic dysfunction or lipid abnormalities. Digital reminders and connected monitoring tools may help owners maintain medication, feeding and testing schedules. Suppliers that coordinate veterinary clinics, diagnostic laboratories and pet nutrition providers can offer a more continuous management pathway than standalone products.
Regulatory scrutiny and competition from established veterinary therapies
Alternative care approaches can compete with dedicated metabolic-health products when owners rely on general wellness foods, home monitoring or delayed veterinary visits instead of structured diagnosis and treatment. Inaccurate home test interpretation may create false reassurance or unnecessary concern, while unsubstantiated supplements can divert spending from clinically appropriate care. Diagnostic providers also face competition from established veterinary laboratories and clinic-owned testing systems. Changes in testing protocols or clinical recommendations can make some products less relevant. Companies must maintain analytical reliability, clear interpretation guidance and compatibility with veterinary workflows to sustain professional confidence.
The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.
The Endocrine and Metabolic Therapeutics segment is expected to be the largest during the forecast period
The Endocrine and Metabolic Therapeutics segment is expected to account for a leading share of the pet metabolic health market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal product category applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.
The Metabolic Comorbidities segment is expected to have the highest CAGR during the forecast period
The Metabolic Comorbidities segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.
North America is expected to account for a leading share of the pet metabolic health market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.
Asia Pacific is expected to exhibit strong growth in the pet metabolic health market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.
Key players in the market
Some of the key players in the Global Pet Metabolic Health Market include Zoetis Inc., Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim Animal Health, Dechra Pharmaceuticals PLC, Ceva Sante Animale, Virbac, Vetoquinol, IDEXX Laboratories, Inc., Antech Diagnostics, Hill's Pet Nutrition, Royal Canin, Nestle Purina PetCare, Nutramax Laboratories, PetMed Express, Inc..
In October 2026, Fera Pets introduced a daily soft chew formulated to support lean muscle, metabolism and body condition in dogs.
In September 2026, American Animal Hospital Association released updated canine diabetes-management guidelines covering diagnosis, insulin treatment, continuous glucose monitoring, dietary management and follow-up care.
In July 2026, Royal Canin (Mars Petcare) launched its first fresh, fully cooked veterinary diet portfolio for dogs, addressing selected gastrointestinal needs, food sensitivities and reduced appetite through veterinarian-exclusive nutrition.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.